Cellular Biomedicine Lung Cancer IND Application Approved

The FDA has approved Cellular Biomedicine’s Investigational New Drug (IND) application for its tumor infiltrating lymphocyte (TIL) drug candidate C-TIL051 for late-stage non-small cell lung cancer patients who have relapsed or had drug resistance to other therapies.

The investigational drug has shown encouraging safety and efficacy results in preclinical studies and will now advance to early stage trials, the company said.

Cellular Biomedicine said it will begin manufacturing the drug in clinical batches in anticipation of the trials.